

5. (Amended) A method according to claim 1, wherein the pore-forming agent is potassium bitartrate, creatine, aspargine, glutamine, aspartic acid, glutamic acid, leucin, neroleucine, inosine, isoleucine, magnesium citrate, magnesium phosphate, magnesium carbonate, magnesium hydroxide, magnesium oxide or a composition wherein at least one component is selected from one of these substances.

6. (Amended) A method according to claim 1, wherein the pore-forming agent is chitosan and poly(butyl methacrylate, (2-dimethyl aminoethyl) methacrylate, methyl methacrylate) 1:2:1.

7. (Amended) A method according to claim 1, wherein the water insoluble polymer is selected from one of the groups of cellulose esters, acrylic polymers, polyvinyl acetates, polyvinyl chlorides or a composition wherein at least one component is selected from one of the groups.

8. (Amended) A method according to claim 1, wherein the coating polymer is ethylcellulose, celluloseacetate, celluloseacetatebutyrate, celluloseacetatepropionate, nitrocellulose, polymethylmethacrylate, poly(ethylacrylate, methylmethacrylate), polyvinylacetate, polyvinylchloride, polyethylene, polyisobutylene, poly(ethylacrylate, methylmethacrylate, trimethylamonioethylmethacrylatchloride), a block- or copolymer of the polymers or a composition wherein at least one of the components is selected from these polymers.

9. (Amended) A method according to claim 1, wherein the coating polymer is a copolymer consisting of 50-100% by weight of polyvinyl chloride and 0-50% by weight of polyvinyl acetate.

10. (Amended) A method according to claim 1, wherein the coating polymer is a copolymer consisting of 80-95% by weight of polyvinylchloride, 0,5-19% by weight of polyvinylacetate and 0,5-10% by weight of polyvinylalcohol.

11. (Amended) A method according to claim 1, wherein the solid core includes at least one drug selected from the group consisting of tranquillizers, antibiotics, hypnotics, antihypertensives, antianginas, analgesics, antiinflamatorics, neuroleptics, antidiabetics, diuretics, anticholinergics, antihyperacidics or antiepileptics, ACE inhibitors  $\beta$ -receptor antagonists and agonists, anaesthetics, anorexiants, antiarrythmics, antidepressants, anticoagulants, antidiarrhoeotics, antihistamines, antimalariaels, antineoplastics, immunosuppressives, antiparkinsonians, antipsychotics, antiplatelets, diuretics, antihyperlipidics.

12. (Amended) A method according to claim 1, wherein the drug for the solid core is potassium chloride, theophylline, a theophylline salt, phenylpropanolamine, sodium salicylate, choline theophyllinate, paracetamole, carbidopa, levodopa, diltiazem, enalapril, verapamil, naproxen, pseudoephedrin, nicorandil, oxybutin, morphine, oxycodone or propranolol.

13. (Amended) A method according to claim 1, wherein the aqueous dispersion includes at most 20%, preferably at most 10% and most preferably at most 5% by weight of organic solvent.

14. (Amended) A method according to claim 1, wherein the obtained coated cores are cured with heat or moisture.

15. (Amended) A method according to claim 1, wherein the pore-former in the coating suspension is stabilized with one or more ionic, non-ionic or polymer surfactants.

16. (Amended) A method according to claim 1, wherein the coating polymer is plasticized.

19. (Amended) Preparation according to claim 17, wherein the amount of the pore-forming agent is 40-95, preferable 50-90% and most preferably 55-88% by weight of the total weight of the dry coating.

20. (Amended) Preparation according to claim 17, wherein the polymer is ethylcellulose, cellulose-acetate, celluloseacetatebutyrate, celluloseacetatepropionate, nitrocellulose, polymethylemethacrylate, poly(ethylacrylate, methylmethacrylate), polyvinylacetate, polyvinylchloride, polyethylene, polyisobutylene, poly(ethylacrylate, methylmethacrylate, trimethylamonioethylmethacrylatchloride), a block- or copolymer of the

polymers or a composition wherein at least one of the components is selected from these polymers.

21. (Amended) Preparation according to claim 17, wherein the coating polymer is a copolymer consisting of 50-100% by weight of polyvinyl chloride and 0-50% by weight of polyvinyl acetate.

22. (Amended) Preparation according to claim 17, wherein the coating polymer is a copolymer consisting of 80-95% by weight of polyvinylchloride, 0,5-19% by weight of polyvinylacetate and 0,5-10% by weight of polyvinylalcohol.

**REMARKS**

The present Amendment is intended to eliminate the use of multiple dependency.

The examination and allowance of the application are respectfully requested.

Respectfully submitted,

BURNS, DOANE, SWECKER & MATHIS, L.L.P.

By: Benton S. Duffett

Benton S. Duffett, Jr.  
Registration No. 22,030

P.O. Box 1404  
Alexandria, Virginia 22313-1404  
(703) 836-6620

Date: March 29, 2001